Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $LCTX
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/20/2024 | $4.00 | Buy | Craig Hallum |
11/2/2022 | $5.00 | Outperform | Robert W. Baird |
6/14/2022 | $4.00 | Buy | B. Riley Securities |
8/19/2021 | $8.00 | Outperform | Noble Capital Markets |
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Safety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a novel delivery device developed to deliver OPC1 directly to the area of injury in patients with spinal cord injury (SCI). OP
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a replay of the presentation on the Events and Presentations section of Lineage's website. Additional videos are available on the Media page of the Lineage website. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Lineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross Proceeds Upon the Full Exercise of OpRegen® Clinical Milestone-linked Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an additional $6 million in gross proceeds at the closin
Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target
Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00
Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target
Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00
B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target
B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00
Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
General Counsel Samuel George A. Iii converted options into 6,076 shares and covered exercise/tax liability with 2,440 shares, increasing direct ownership by 16% to 25,820 units (SEC Form 4)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
President and CEO Culley Brian M converted options into 31,249 shares and covered exercise/tax liability with 12,547 shares, increasing direct ownership by 10% to 213,544 units (SEC Form 4)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
SEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.
DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
SEC Form PRE 14A filed by Lineage Cell Therapeutics Inc.
PRE 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Lineage Announces Appointment of General Counsel
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on November 14, 2024, by dialing (800) 715-9871 from the U.S. an
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program OPC1 Clinical Study Start Up Preparations Ongoing Hosted 2nd Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 fi
Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)